Health
Breakthroughs and beating the odds.
CRISPR Therapy CTX310 Reduces LDL Cholesterol by Over 50 Percent for One Year in Trial
A single infusion of the CRISPR-Cas9 therapy CTX310 achieved significant and sustained reductions in LDL cholesterol and triglycerides during a Phase 1a clinical trial for lipid disorders.
Ensitrelvir shows 67% reduction in COVID-19 risk in trial
Ensitrelvir reduced the risk of symptomatic COVID-19 by 67% in a phase 3 trial, aiding high-risk participants significantly.
WHO Reviews Malaria Vaccine Pipeline with Two Prequalified
WHO's review identifies two prequalified malaria vaccines among 147 candidates, advancing global health efforts.
GSK and Ionis Report Successful Hepatitis B Treatment Trial
GSK and Ionis announced a 19% functional cure rate for hepatitis B with their drug bepirovirsen in Phase 3 trials.
Gene-editing therapy shows significant promise for sickle cell disease
A clinical trial found that 27 of 28 participants treated with reni-cel gene therapy had no vaso-occlusive crises.
USF Health Discovers New Malaria Vaccine Target
Researchers at USF Health identify a new vulnerability in the malaria parasite for potential vaccine development.
Bepirovirsen shows 19% functional cure rate in hepatitis B trials
GSK's bepirovirsen shows promising results with a 19% functional cure rate for chronic hepatitis B.
Moderna and Merck Report Positive Phase 3 Results for mRNA Cancer Vaccine
Moderna and Merck's mRNA cancer vaccine shows promise in reducing melanoma recurrence in a Phase 3 trial.
Multistage Malaria Vaccine Shows Favorable Early Trial Results
A new malaria vaccine demonstrated a favorable safety profile in early human trials, showing promising protective efficacy.
UCLA Trial Reports Strong Results for Off-the-Shelf Cancer Vaccine
A new cancer vaccine shows promise in patients with pancreatic and colorectal cancer, enhancing immune responses against KRAS mutations.
University of Cambridge Completes First Human Trial of Sarbecovirus Vaccine
Cambridge researchers completed a human trial of pEVAC-PS, an AI-designed vaccine against sarbecoviruses, showing safety and modest immune responses.
In vivo CAR-T therapy shows promise for multiple sclerosis
A clinical trial found that in vivo CAR-T therapy improved symptoms in participants with multiple sclerosis and autoimmune conditions.
WHO Launches Childhood Cancer Survival Data Portal
WHO releases first global survival estimates for childhood lymphoid leukaemia across 194 countries.
Timor-Leste Achieves Elimination of Trachoma as Health Problem
Timor-Leste has been validated by WHO for eliminating trachoma, the leading infectious cause of blindness.
Moderna and Merck's mRNA Melanoma Vaccine Shows Success in Trial
Moderna and Merck's personalized mRNA vaccine met key endpoints in a Phase 3 trial for melanoma treatment.
Wolbachia Mosquito Release Reduces Dengue Cases by Over 70%
A trial in Singapore shows Wolbachia-infected mosquitoes cut dengue risk by 71-72% among over 700,000 residents.
WRSs2 Shigella vaccine shows 89% protection in trial
A trial of the WRSs2 Shigella vaccine achieved 89% efficacy with two doses, the highest for any candidate.
Big Catch-Up initiative delivers over 100 million childhood vaccine doses
The Big Catch-Up initiative successfully delivered over 100 million vaccine doses to millions of children across 36 countries.
Rotavirus vaccine significantly reduces gastroenteritis deaths
Rotavirus vaccination reduces mortality from gastroenteritis by 75.8% in children, according to a global study.
Thailand achieves rubella elimination as a public health problem
Thailand has been verified by WHO for eliminating rubella as a public health issue as of September 2026.
FDA approves CRISPR gene therapy Casgevy for children 2+
The FDA has approved Casgevy for children 2 and older with sickle cell disease or β-thalassemia.
Johns Hopkins Vaccine Trial Shows Promise for Pancreatic Cancer Prevention
The mKRAS-VAX vaccine trial by Johns Hopkins achieved a 90% immune response rate in high-risk participants.
Gene therapy shows 95% success in treating ADA-SCID in children
A UCLA-led gene therapy restored immune function in 59 of 62 children with ADA-SCID, marking a significant medical breakthrough.
Gene therapy successfully restores immune function in children with ADA-SCID
A gene therapy trial has restored immune function in 95% of children with ADA-SCID, offering new hope for treatment.
Bepirovirsen Trials Show Promising Results for Hepatitis B
GSK's bepirovirsen achieved functional cure rates of 19-20% in phase 3 trials for chronic hepatitis B.
Personalized mRNA Cancer Vaccine Shows Success in Phase 3 Trial
Merck and Moderna reported that their mRNA cancer vaccine met key trial endpoints for melanoma treatment.
Bepirovirsen achieves 19% functional cure rate in chronic hepatitis B
GSK's bepirovirsen shows a 19% functional cure rate in chronic hepatitis B after treatment cessation, as per phase 3 trials.
Chile becomes first South American country to eliminate rabies
Chile is the first South American nation validated by WHO for eliminating dog-transmitted rabies as a public health issue.
Pfizer and Valneva Lyme Disease Vaccine Shows 73% Efficacy
The phase 3 VALOR trial of Lyme disease vaccine PF-07307405 shows 73.2% efficacy after four doses.
Experimental Drug Shows Promise in Treating Mesothelioma
An experimental drug controls disease progression in 67% of mesothelioma patients in a phase 1 trial.
Gene therapy restores immune function in 95% of ADA-SCID children
A gene therapy trial successfully restored immune function in 96% of children with ADA-SCID, a rare immune disorder.
FDA approves Kresladi gene therapy for rare immune disorder
Kresladi, a new gene therapy, gains FDA approval for treating severe leukocyte adhesion deficiency-I, improving patient outcomes.
Phase 3 trial shows promise for personalized mRNA cancer vaccine
Merck and Moderna's cancer vaccine, intismeran autogene, meets key endpoints for melanoma treatment.
India exceeds 8 million HPV vaccinations in national campaign
India has administered over 8 million doses of the HPV vaccine to girls as part of a national health initiative.
Bepirovirsen Shows Promise for Chronic Hepatitis B Cure
Bepirovirsen achieves functional cure rates of up to 26% in Phase 3 trials for chronic hepatitis B.
FDA Approves Ensitrelvir as First Oral Antiviral for COVID-19 Prevention
The FDA has approved ensitrelvir for COVID-19 post-exposure prevention in adults and adolescents.
Gene Therapy Restores Immune Function in 95% of Children with ADA-SCID
A gene therapy has restored immune function in 59 of 62 children with ADA-SCID, offering hope for a deadly genetic disorder.
Moderna's mRNA flu vaccine approved for adults 50 and older
The FDA has approved Moderna's mFLUSIVA, the first mRNA flu vaccine, for adults aged 50 and above.
Lancet Review Confirms Safety and Effectiveness of mRNA Vaccines
A Lancet review confirms mRNA vaccines are 87% effective against SARS-CoV-2 infections.
NOUS-209 vaccine shows promise in preventing Lynch syndrome cancers
Early data indicates the NOUS-209 vaccine may prevent cancers related to Lynch syndrome.
Wolbachia mosquito releases greatly reduce dengue risk in Singapore
A trial in Singapore shows Wolbachia-infected mosquitoes cut dengue rates by over 70%.
WRSs2 Shigella Vaccine Shows 89% Efficacy in Phase 2 Trial
The WRSs2 oral Shigella vaccine demonstrated 89% efficacy in a Phase 2 trial, marking a significant advancement in vaccine development.
FDA Approves First mRNA Seasonal Influenza Vaccine for Seniors
Moderna's mFlusiva is the first mRNA influenza vaccine approved for adults 50 and older.
Oxford Vaccine Group advances Bundibugyo Ebola vaccine to trials
The Oxford Vaccine Group has completed preclinical testing for a Bundibugyo Ebola vaccine and is set for phase I trials.
GSK's Bepirovirsen Shows 19% Functional Cure in Hepatitis B Trials
GSK's bepirovirsen demonstrated a 19% functional cure rate in hepatitis B phase 3 trials.
mKRAS-VAX vaccine shows promise in pancreatic cancer trial
A phase 1 trial of the mKRAS-VAX vaccine demonstrated a durable immune response in 90% of high-risk pancreatic cancer patients.
FDA Approves Xocova as First Oral Therapy for COVID-19 Prevention
Xocova becomes the first oral therapy approved by the FDA for COVID-19 post-exposure prophylaxis in adults and adolescents.
Novavax's XFG-variant COVID-19 vaccine approved in multiple regions
Novavax's XFG variant-adapted vaccine receives approvals for the 2026-2027 season in the US, EU, and Japan.
GSK and Ionis report Phase 3 success for hepatitis B treatment
GSK and Ionis announce successful Phase 3 trials for bepirovirsen, a potential treatment for chronic hepatitis B.
NOUS-209 Vaccine Shows Promise for Lynch Syndrome Cancer Prevention
Early trials of the NOUS-209 vaccine indicate it can induce T-cell responses against cancer in Lynch syndrome patients.